Confidential

INFUSION 51A FUNDINVESTOR PRESENTATION

FORWARD-LOOKING STATEMENTS

This presentation does not constitute an offer to sell or the solicitation of any offer to buy interests in Infusion 51a, LP, which may only be made at the time a qualifiedsubscriber receives the Private Placement Memorandum (PPM) describing the offering. In the case of any inconsistency between the descriptions or terms in thispresentation and the PPM, the PPM shall control. An investment in Infusion 51a, LP involves significant risks, including the loss of the entire investment. Restrictions applyto transfers and withdrawals of shares in the offering. Before deciding to invest in the offering, prospective investors should read the PPM and pay particular attention to therisk factors contained in the PPM. Prospective investors should make their own investigation and evaluation of the information contained in this presentation. Eachprospective investor should consult their own attorney, business adviser and tax adviser as to legal, business, tax and related matters concerning the information containedherein. Certain information contained in this presentation constitutes “forward-looking statements,” which can be identified by the use of forward-looking terminology suchas “may,” “will,” “should,” “expect,” “anticipate,” “target,” “project,” “estimate,” “intend,” “continue” or “believe,” or the negatives thereof or other variations thereon or comparableterminology. Due to various risks and uncertainties, actual events or results may differ materially from those reflected or contemplated in such forward-looking statements.Certain information contained in this presentation is based on or derived from information provided by independent third-party sources. Infusion 51a, LP believes that suchinformation is accurate and that the sources from which it has been obtained are reliable. Infusion 51a, LP cannot guarantee the accuracy of such information, however, andhas not independently verified the assumptions on which such information is based. This presentation is being provided on a confidential basis. Accordingly, this presentationmay not be reproduced in whole or in part, and may not be delivered to any person without the prior written consent of Infusion 51a, LP. Past performance is not indicativeof future results.

2

An Impact FundAn impact investment approach

Our Portfolio

Theralink Technologies IncProtein mapping to aid biomarker development & support personalized treatment options

Vivacitas OncologyDrug development with personalized approach

SHARED BELIEFS & VISIONS

PATIENTS

01

02SHAREHOLDERS

& BUSINESS PARTNERS

03FOUNDERS &

MANAGEMENT TEAM

3

Diagnostic Company PENDINGCOVID-19 testing & precision-based cancer diagnostics

500000

450000

4

Diagnostic for COVID-19

POINT OF CARE TESTING•Shanghai Liangrun test•Screening point of care test•Sensitivity 90.43% and specificity 100%•Result in 2-10 minutes•Measures IgG & IgM antibodies•Prescribed testing schedule for individuals •Manufacture 300,000 kits/day•Exclusive agreement for US & Israel

5

Diagnostic for COVID-19

500000

450000

6

Diagnostic for COVID-19

CONFIRMATORY TESTING• 3D Medcare anchor test • Nucleic acid PCR via nasopharyngeal swab• Sensitivity 99.3% and specificity 100%• Kit combines COVID-19 +/- flu testing + countertop box• FDA approval pending

CLIENT ADOPTION• Utilized by over 30 pharmaceutical & bio-tech companies• Validated assay in breast cancer

NEW LEADERSHIP• Experienced CEO & Board• Exclusive license with George Mason University

DRIVERSNIH technology• Re-engage with Big Pharma• Oncologists & Cancer Hospitals• Service Agreements• Royalty Streams

* There is no guarantee that Infusion 51a’s objectives will be realized** There is no assurance that any of the above strategy will be successful

7

• Intended applications include determination of whether a prescribed medication may be effective in treating the right patient at the right time

• Highly sensitive analyses of identified biomarkers has the potential to empower physicians to improve treatment decisions through better prediction of treatment outcomes

• Could prevent the patient from being exposed to cytotoxic treatments that may be unlikely to deliver clinically meaningful benefits, while guiding physicians to prescribing treatments that may be likely to yield maximum results

TheraLink’s® Advantage

P

RTKs

P

P

P

P

Signal Molecules

Cell Growth

Current Interest in the Theralink AssayBiopharma ClientsPhysicians

• Key Opinion Leaders (KOL’s)• Oncologists

8

ASSET DRIVERS• Known mechanism of action• Improved chemistry• Phase 2 trials completed• Need in rare diseases

VISION• Focused execution strategy in Glioblastoma (GBM)• Differentiated clinical plan• Close execution oversight• High fiscal responsibility

NEW LEADERSHIP• Experienced team & Board• Key Scientific and Medical Advisors

Vivacitas Oncology

* There is no guarantee that Infusion 51a’s objectives will be realized** There is no assurance that any of the above strategy will be successful

9

AR-67: PERSONALIZED APPROACH FOR COMBATING GLIOBLASTOMA MULTIFORME

Plan

Attractive Chemistry• NextGen Camptothecin• Highly potent• Improved safety over alternatives• Lipophilic – potential for crossing BBB

Regulatory Progress• Phase 1 and 2 clinical studies completed• 74 patients dosed• ODE granted

Potential Personalized TherapyApproach• Blood-based GBM biomarkers known• Molecular oncologists actively engaged• Build on Theralink’s competency and

successes• Gain IP on drug specific biomarkers

Phase 3 Execution Readiness• Differentiated clinical plan• Highly engaged with KOLs & Advisors• ID biomarkers to achieve high response rate

Ph 1 Al terna ti ve Dos e Study Ph 2 Ph 3

10

HOW IS THE VALUE OF THE FUND DETERMINED?• INFUSION 51A makes investments into public and private companies.• We favor discount investing in private and public companies, owning late-stage

assets, with demonstrable efficacy. We take an active position in leadership ofour companies and set clear milestones to allow opportunities for favorablerisk-reward dynamics for our investors.

• The Fund uses an independent valuation firm to calculate the NAV.

* There is no guarantee that Infusion 51a’s objectives will be realized** Past performance is not an indication of future performance*** We may not be successful in achieving inter-sector synergy or achieve our value proposition**** Exact amount dependent on valuation and disposition of assets***** AR-67 may not obtain the necessary governmental approval to treat any of the indications

****** There is no assurance that any of the above strategy will be successful******* There is no assurance that any of the agents acquired or developed by

Vivacitas will obtain the necessary governmental approval to treat any of the indications******** All forecast and projections are speculative and may not be relied on for accuracy

11

WHAT IS THE RETURN OBJECTIVE FOR THE FUND?Targeting 8X-10X of committed capital/invested capital

WHAT DO YOU CURRENTLY OWN?• 80% of Vivacitas Oncology• Up to 20% of Diagnostic Company containing Covid 19 tests (pending)• 8% of Theralink Incorporated

HOW WILL THE FUND USE THE CAPITAL RAISED?The Fund plans on investing:• $3-5M into Vivacitas to facilitate the design of next FDA approved clinical trial• $1M into Theralink to operationalize the newly built lab and begin servicing biopharmaceutical companies.• $2-5M into Diagnostic Company• Additional capital will be invested in future portfolio companies to drive diversification and growth

and will act as reserves for our current investments.

POTENTIAL VALUE DRIVERS

VIVACITAS• FDA approved clinical protocol (Q4)• Securing sites for our clinical trials (initiated)• Dosing the first patient (Q1 2021)• Interim data read-out• Expand into different clinical indications

(initiated)• Acquiring additional assets

THERALINK• Opening the lab (completed)• Servicing pharma (started)• Gaining CAP/CLIA Certification (Q3)• Providing oncologist testing for patients• Companion diagnostic with a therapeutic company• Insurance company acceptance of diagnostic for reimbursement

* There is no guarantee that Infusion 51a’s objectives will be realized** Past performance is not an indication of future performance*** We may not be successful in achieving inter-sector synergy or achieve our value proposition**** Exact amount dependent on valuation and disposition of assets

12

***** AR-67 may not obtain the necessary governmental approval to treat any of the indications

****** There is no assurance that any of the above strategy will be successful******* There is no assurance that any of the agents acquired or developed by

Vivacitas will obtain the necessary governmental approval to treat anyof the indications

******** All forecast and projections are speculative and may not be relied on for accuracy

DIAGNOSTIC COMPANY• Receive FDA approval on COVID-19 tests

• Market and distribute tests• National clinical adoption• Reimbursement• NASDAQ listing (Q3)

WHAT ARE POTENTIAL EXIT STRATEGIES?

• Selling part of our equity to third parties• Licensing deals (e.g., Canada, Europe, Japan, and/or China)• Commercialization • Initial public offering (IPO)• Acquisition of the portfolio company• JV• Royalty

* There is no guarantee that Infusion 51a’s objectives will be realized** Past performance is not an indication of future performance*** We may not be successful in achieving inter-sector synergy or achieve our value proposition**** Exact amount dependent on valuation and disposition of assets

13

***** AR-67 may not obtain the necessary governmental approval to treat any of the indications

****** There is no assurance that any of the above strategy will be successful******* There is no assurance that any of the agents acquired or developed by

Vivacitas will obtain the necessary governmental approval to treat any of the indications******** All forecast and projections are speculative and may not be relied on for accuracy

COMPARABLE COMPANIESTheralink:COMPANY VALUE VALUE DETERMINED BY

Nanostring$920Mas of 4/6/20

$9.2Bas of 4/6/20

$268Mas of 4/6/20

NSDAQ

NSDAQ

$5.5B Sold to RocheFoundation Medicine

Exact Science

Vivacitas:COMPANY VALUE VALUE DETERMINED BY

Syndax $302Mas of 4/6/20

NSDAQ

NSDAQ

Sold to Novartis$8.7B

Spectrum

AveXis

* There is no guarantee that Infusion 51a’s objectives will be realized** Past performance is not an indication of future performance*** We may not be successful in achieving inter-sector synergy or achieve our value proposition**** Exact amount dependent on valuation and disposition of assets

14

***** AR-67 may not obtain the necessary governmental approval to treat any of the indications

****** There is no assurance that any of the above strategy will be successful******* There is no assurance that any of the agents acquired or developed by

Vivacitas will obtain the necessary governmental approval to treat any of the indications******** All forecast and projections are speculative and may not be relied on for accuracy

HISTORICAL PERFORMANCE

ENDING GROSS(1)Ending Gross Return is calculated by taking NAV before management fees and expenses are taken out

ENDING NET(2)Ending Net Return is calculated by taking NAV after management fees and expenses are taken out

Date

15-May

Open Gross Ending Gross Ending Net Net ITD

$100,000 $99,833 $99,833 0.-17%

ASSUMPTIONS•2.0% Management Fee (monthly in arrears) 20% Performance Fee•Gross return calculated by taking the fund Net Asset Value (NAV) before management fees and expenses are taken out

•Net return calculated by taking the Funds Gross net of funds expenses management fee, and performance fee

Note: returns will vary significantly depending on capital, timing, and if side pocket participation is used.

* From May 2015 to December 30, 2018, a hypothetical $100,000 investment would havean unrealized gain of 277.34%. This chart was run by the fund administrator TridentTrust.

500000

450000

400000

350000 15-Dec $112,417 $120,706 $116,565 16.56%300000 16-Jun $117,958 $116,442 $113,153 13.15%250000 16-Dec $147,664 $141,315 $133,052 33.05%200000 17-Jun $450,594 $450,188 $380,150 280.15%150000

10000050000

17-Dec $445,115 $440,183 $372,147 272.15%18-Jun $432,730 $436,177 $368,941 268.94%

0 18-Sep $434,301 $433,007 $366,405 266.41%May - 15 Dec-15 Jun-16 Dec-16 Jun-17 Dec-17 Jun-18 Sep-18 Dec-18 18-Dec $432,509 $446,680 $377,344 277.34%

15

FundAdministrationAuditors

Securities CounselJeff StephensChief Investment Officer• Infusion 51a Co-founder• International Infusion: Co-founder• Vivacitas: Co-founder & Director• Theralink: Director

General Partner• Northwestern: Associate

Professor of Surgery• Northwestern: Director,

Center of GlobalSurgery• Sadanah Foundation: Founder• Vivacitas: Interim CEO

Mamta Swaroop, MD,FACS, FICS Brett Logan,JDScott VanderMeer, MBAManaging Partner• Infusion 51a Co-founder• International Infusion: Co-founder• Vivacitas: Co-founder, Director

and CFO

• Theralink: Former Interim CFO

Team

16

FUND SUMMARY

* There is no guarantee that Infusion 51a’s objectives will be realized** Past performance is not an indication of future performance*** We may not be successful in achieving inter-sector synergy or achieve our value proposition**** Exact amount dependent on valuation and disposition of assets***** AR-67 may not obtain the necessary governmental approval to treat any of the indications

****** There is no assurance that any of the above strategy will be successful******* There is no assurance that any of the agents acquired or developed by

Vivacitas will obtain the necessary governmental approval to treat any of the indications******** All forecast and projections are speculative and may not be relied on for accuracy

17

FundInvestment managerTarget raiseInvestment by GPClosing dateMinimum commitmentMaximum commitmentSubsequent closingsTermLockupCarried interestManagement fee

• Infusion 51a LP, a Delaware limited partnership• International Infusion Holdings LLC, an Illinois limited liability company• $20 million• 21% • Q2 2020• $100,000• $6 million• Open ended at GP’s discretion• Evergreen• 5 years with potential for early distributions• 20%, after return of contributed capital• 2% per annum

DISCLAIMERS & RISK FACTORS

Not an Offer of Securities: The information provided in this presentation is for informational purposes only and is not intended to be, nor should it be considered to be, an advertisement or an offer or a solicitation of an offer to buy or sell any securities. The information herein, or upon which opinions have been based, has been obtained from sources believed to be reliable, but no representations, expressed or implied, or guarantees, can be made as to their accuracy, timeliness or completeness. All opinions and information set forth herein are subject to change without notice. Past performance should not be taken as an indication or guarantee of future performance, and no representation or warranty is made regarding future performance. Before entering into any transaction, you should take steps to ensure that you understand and have made an independent assessment of the appropriateness of the transaction in light of your own objectives and circumstances, including the possible risks and benefits of entering into such transaction. You should also consider making such independent investigations by discussing the transaction with your professional tax, legal, accounting, and other advisors.

Non-public Information: The information provided in this presentation is for informational purposes only and is not intended to be, nor should it be, used for public trading in the portfolio company’s securities. The recipient of this presentation agrees to be prohibited from trading in the portfolio company’s securities until after the information herein has been disclosed publicly by authorized filings and/or press releases made by the Company.

Accredited Investors: All Fund investors must qualify as Accredited Investors, as defined by U.S. law.

Confidentiality: All information contained within this presentation is considered confidential with further distribution strictly prohibited without consent.

INVESTMENT IN Infusion 51A, LP MAY NOT BE SUITABLE FOR ALL INVESTORS. EACH POTENTIAL INVESTOR IN INFUSION 51A, LP MUST DETERMINE THE SUITABILITY OF THEIR INVESTMENT IN LIGHT OF HIS/HER/ITS OWN UNIQUE CIRCUMSTANCES. IN PARTICULAR, EACH INVESTOR SHOULD:

have sufficient knowledge and experience to make a meaningful evaluation of the interests offered herein, the merits and risks of purchasing such interests, and the information contained or incorporated by reference into this Memorandum and/or any applicable supplement;have access to, and knowledge of, appropriate analytical tools to evaluate, in the context of his/her/its particular financial situation, an investment in Infusion 51a, LP and the impact such investment will have on his/her/its overall investment portfolio;have sufficient financial resources and liquidity to bear all of the risks of an investment in Infusion 51a, LP or where the currency for payments is different from the potential investor’s currency; understand thoroughly the terms of the offering of interests in Infusion 51a, LP and be familiar with the behavior of any relevant indices and financial markets; andbe able to evaluate (either alone or with the help of a financial advisor) possible scenarios for economic, interest rate, and other factors that may affect its investment and its ability to bear applicable risks.

POTENTIAL LOSS OF INVESTMENT:An investment in Infusion 51a, LP is speculative and involves a high degree of risk, and there can be no assurance that Infusion 51a, LP will achieve its investment objectives. In fact, the practices of short-selling, leverage and limited diversification, can, in certain circumstances, maximize the adverse effects to which Infusion 51a, LP investment portfolio may be subject.

POTENTIAL INVESTORS COULD LOSE ALL OR A SUBSTANTIAL PORTION OF THEIR INVESTMENTS IN IFUSION 51A,LP.POTENTIAL INVESTORS SHOULD CONSIDER ILLIQUIDITY OF THE FUND BEFORE INVESTING. ILLIQUID ASSETS MAY BE HARD TO SELL AND MIGHT NOT HAVE A PLATFORM TO SELL THEASSETS IN A TIMELY MATTER, IFAT ALL.

18